3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
1
CNS
1
Conditions
Neoplasms
4
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Lymphoproliferative Disorders
2
Glioma
2
Melanoma
1
Locally Advanced Thyroid Gland Carcinoma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
atezolizumab
3
fludarabine
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Pemetrexed
2
Nivolumab
2
Cisplatin
2
spartalizumab
1
repotrectinib
1
pertuzumab
1
lutetium Lu 177 dotatate
1
gilteritinib
1
enzalutamide
1
durvalumab
1
copper dotatate CU-64
1
cemiplimab
1
Trastuzumab
1
Sodium Chloride
1
Radiotherapy
1
Radiosurgery
1
Mitomycin
1
Lutetium-177
1
Lutetium
1
Injections
1
Idarubicin
1
HuMax-IL8
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Histologic Type
×
entrectinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled